FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Overdose Crisis Gets Priority in CDER Report

CDER director Patrizia Cavazzoni says the 2023 Drug Safety Priorities report focuses on the nations drug overdose crisis.

latest-news-card-1
Human Drugs

PhRMA Seeks More FDA Info on Rare Disease Steps

Pharmaceutical Research and Manufacturers of America asks FDA to take some specific follow-up steps to its virtual meeting on advancing the developmen...

latest-news-card-1
Human Drugs

FDA Outlines Biosimilar Educational Outreach

FDA increases its educational outreach to decrease hesitancy with biosimilar usage.

latest-news-card-1
Human Drugs

Mesoblast Wins Orphan Status for Revascor

FDA grants Mesoblast an orphan-drug designation for Revascor (rexlemestrocel-L) and its use in children with congenital heart condition hypoplastic le...

latest-news-card-1

FDA Late with Diversity Plan Guidance

A Regulatory Affairs Professionals Society online post says FDA is several weeks late in delivering a congressionally mandated guidance on clinical tr...

latest-news-card-1
Human Drugs

Fast Track for Type 1 Diabetes Drug

FDA grants Diamyd Medical a fast-track designation for Diamyd (rhGAD65/alum) and its use in improving glycemic control in some diabetes patients.

latest-news-card-1
Medical Devices

Merit Medicals SCOUT Surgical Guide Cleared

FDA clears a Merit Medical Systems 510(k) for the SCOUT MD Surgical Guidance System for use in implanting surgical reflectors in abnormal breast tissu...

latest-news-card-1
Federal Register

Charging for Drugs Under an IND Guidance

FDA makes available a final guidance entitled Charging for Investigational Drugs Under an IND: Questions and Answers.

latest-news-card-1
Federal Register

FDA Digital Transformation Office Reorganization

Federal Register notice: FDA announces that its Office of Digital Transformation has modified its organizational structure.

latest-news-card-1
Human Drugs

Professor Blasts FDA on Harmful Supplements

Harvard Medical School professor Peter Cohen blasts FDA for a lack of sufficient action to remove harmful dietary supplements from the marketplace.